The Food and Drug Administration last week authorized marketing of a rapid diagnostic test to detect Ebola virus antigens in human blood from certain living individuals as well as samples from those recently deceased who are suspected to have died from Ebola. The OraQuick Ebola Rapid Antigen Test is the first rapid diagnostic test that the FDA has allowed to be marketed in the U.S. for the Ebola Virus Disease. “Today’s marketing authorization provides another important tool in the effort to fight Ebola,” said FDA Acting Commissioner Ned Sharpless, M.D. “…This marketing authorization may provide additional assurances to health care professionals seeking to use these types of rapid diagnostics. The ability to use this test to promptly make a presumptive Ebola diagnosis could help providers to more quickly isolate patients and begin treatments that can be potentially life-saving.”

Related News Articles

Headline
The Centers for Disease Control and Prevention today identified vitamin E acetate as a “potential chemical of concern” in biologic samples from patients with…
Headline
The Food and Drug Administration yesterday approved the first test to use next generation sequencing technology to detect HIV drug-resistance mutations in…
Headline
The Centers for Disease Control and Prevention yesterday updated the number of people with confirmed or probable lung injuries associated with electronic…
Headline
The Health Resources and Services Administration Friday awarded cities, counties, states and community organizations $2.27 billion in fiscal year 2019 grants…
Headline
The Centers for Disease Control and Prevention yesterday updated the number of people with confirmed or probable lung injuries associated with electronic…
Headline
The Centers for Disease Control and Prevention today released updated interim clinical guidance for U.S. health care providers evaluating and caring for…